THE HIDDEN PHENOMENON OF OXIDATIVE STRESS DURING TREATMENT OF SUBCLINICAL-MILD HYPOTHYROIDISM: A PROTECTIVE NUTRACEUTICAL INTERVENTION.

Tomella C, Catanzaro R, Illuzzi N, Cabeca A, Zerbinati N, Celep G, Milazzo M, Sapienza C, Italia A, Lorenzetti A, Marotta F.

Source

ReGenera Research group for Aging Intervention, Milano, Italy

 

Abstract

Recent studies suggest that subjects with hypothyroidism under therapy with L-T4 might develop oxidative stress. The aim of this study was to test a redox-balance modulator, FPP, together with subclinical (SH) or mild hypothyroidism (MH) treatment in view of biochemical changes. 60 females treated for SH-MH were divided into two matched groups and received either FPP 3gr 1 sachet t.i.d. or placebo for 3 months. A significant baseline increase of all oxidative markers was observed in SH-MH (p<0.05 vs control) and even more under T4 treatment (p<0.05). FPP caused a normalization of redox markers (p<0.01 vs placebo). Thyroid supplementation accelerates mitochondrial oxygen consumption and oxidative stress while a redox-modulator therapy is advisable, given the long-lasting treatment in such cases.

PMID: 24050492 [PubMed – as supplied by publisher]